Payment overview · 2025
General Payments
$2,026.30
109 reported records · 21 companies
Healthcare provider profile · identity verified
Eric Arnett
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner|Family · OWASSO, OK · NPI 1205235363
Verified facts
What the public records show
CMS Open Payments records show Eric Arnett received $2,026.30 in general payments during 2025 across 109 reported records.
Novo Nordisk Inc accounted for 16.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 42 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Farxiga, Linzess, Mounjaro, Ozempic, Trelegy Ellipta, Trulicity, Vraylar.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Vraylar by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Symbicort by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 75 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 99 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 107 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 65 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 81 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $331.61 | 16.4% | 16 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $288.18 | 14.2% | 17 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $189.48 | 9.3% | 11 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $163.13 | 8.1% | 5 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $151.13 | 7.5% | 11 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $140.91 | 7.0% | 5 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $137.82 | 6.8% | 11 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $92.02 | 4.5% | 5 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $89.99 | 4.4% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $78.61 | 3.9% | 5 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $64.18 | 3.2% | 4 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $62.31 | 3.1% | 3 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $45.46 | 2.2% | 2 | 2025 |
| Corium, LLC | Unresolved — no canonical attribution shown | $42.92 | 2.1% | 2 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $31.85 | 1.6% | 2 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $31.02 | 1.5% | 2 | 2025 |
| Paratek Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $19.79 | 1.0% | 1 | 2025 |
| Collegium Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $18.11 | 0.9% | 1 | 2025 |
| Ardelyx, Inc. | Unresolved — no canonical attribution shown | $17.68 | 0.9% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $16.55 | 0.8% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $13.55 | 0.7% | 2 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $2,026.30 | 109 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $252.35 | 15 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $189.48 | 11 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $154.05 | 5 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $140.91 | 5 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $137.82 | 11 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $129.55 | 3 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $128.10 | 8 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $124.25 | 7 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $123.12 | 10 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $107.45 | 2 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $92.02 | 5 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $89.99 | 2 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $86.88 | 6 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $86.88 | 6 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $66.93 | 4 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $64.22 | 4 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $64.18 | 4 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $54.05 | 3 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $45.29 | 2 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $45.29 | 2 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $44.75 | 3 | 2025 |
Source payment records
|
|||||
| Azstarys Normalized: azstarys |
Drug | Corium, LLC | $42.92 | 2 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $35.83 | 2 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $35.83 | 2 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $31.85 | 2 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $31.02 | 2 | 2025 |
Source payment records
|
|||||
| Symbravo Normalized: symbravo |
Drug | Axsome Therapeutics, Inc. | $30.95 | 1 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $30.75 | 2 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $20.35 | 1 | 2025 |
Source payment records
|
|||||
| NUZYRA Normalized: nuzyra |
Drug | Paratek Pharmaceuticals, Inc. | $19.79 | 1 | 2025 |
Source payment records
|
|||||
| Jornay PM Normalized: jornay pm |
Drug | Collegium Pharmaceutical, Inc. | $18.11 | 1 | 2025 |
Source payment records
|
|||||
| IBSRELA Normalized: ibsrela |
Drug | Ardelyx, Inc. | $17.68 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $17.02 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $16.55 | 1 | 2025 |
Source payment records
|
|||||
| VIBERZI Normalized: viberzi |
Drug | ABBVIE INC. | $16.00 | 1 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $14.51 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $14.39 | 1 | 2025 |
Source payment records
|
|||||
| BEXSERO Normalized: bexsero |
Biological | GlaxoSmithKline, LLC. | $14.39 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $14.39 | 1 | 2025 |
Source payment records
|
|||||
| TRULICITY Normalized: trulicity |
Drug | Lilly USA, LLC | $13.71 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $13.55 | 2 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $4.75 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 81 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 23 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 16 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 107 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 65 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 75 | exact normalized | Medicare Part D |
| TRULICITY trulicity |
2025 | Trulicity | 2024 | 20 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| VRAYLAR vraylar |
2025 | Vraylar | 2024 | 16 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
75 | 12 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
99 | 19 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
107 | 19 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
65 | 17 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
81 | 19 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 410 | 126 |
| Amlodipine Besylate | Amlodipine Besylate | 181 | 53 |
| Metoprolol Succinate | Metoprolol Succinate | 173 | 48 |
| Lisinopril | Lisinopril | 170 | 47 |
| Gabapentin | Gabapentin | 169 | 54 |
| Omeprazole | Omeprazole | 160 | 47 |
| Levothyroxine Sodium | Levothyroxine Sodium | 147 | 46 |
| Montelukast Sodium | Montelukast Sodium | 126 | 39 |
| Losartan Potassium | Losartan Potassium | 124 | 45 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 121 | 40 |
| Metformin Hcl Er | Metformin Hcl | 110 | 27 |
| Pantoprazole Sodium | Pantoprazole Sodium | 108 | 36 |
| Glipizide Er | Glipizide | 107 | 31 |
| Mounjaro | Tirzepatide | 107 | 19 |
| Trazodone Hcl | Trazodone Hcl | 105 | 38 |
| Duloxetine Hcl | Duloxetine Hcl | 100 | 27 |
| Jardiance | Empagliflozin | 99 | 19 |
| Furosemide | Furosemide | 95 | 32 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 94 | 28 |
| Sertraline Hcl | Sertraline Hcl | 92 | 25 |
| Potassium Chloride | Potassium Chloride | 88 | 37 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 87 | 39 |
| Alendronate Sodium | Alendronate Sodium | 86 | 24 |
| Eliquis | Apixaban | 81 | 19 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 80 | 23 |
| Carvedilol | Carvedilol | 79 | 24 |
| Metformin Hcl | Metformin Hcl | 77 | 26 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 75 | 12 |
| Donepezil Hcl | Donepezil Hcl | 72 | 15 |
| Spironolactone | Spironolactone | 68 | 21 |
| Fluoxetine Hcl | Fluoxetine Hcl | 65 | 20 |
| Meloxicam | Meloxicam | 65 | 20 |
| Ozempic | Semaglutide | 65 | 17 |
| Metoprolol Tartrate | Metoprolol Tartrate | 64 | 19 |
| Amitriptyline Hcl | Amitriptyline Hcl | 63 | 12 |
| Tamsulosin Hcl | Tamsulosin Hcl | 62 | 23 |
| Tizanidine Hcl | Tizanidine Hcl | 62 | 36 |
| Escitalopram Oxalate | Escitalopram Oxalate | 59 | 14 |
| Hydrochlorothiazide | Hydrochlorothiazide | 57 | 18 |
| Memantine Hcl | Memantine Hcl | 52 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 52 | 13 |
| Allopurinol | Allopurinol | 50 | 14 |
| Clopidogrel | Clopidogrel Bisulfate | 50 | 16 |
| Nortriptyline Hcl | Nortriptyline Hcl | 46 | 11 |
| Diclofenac Sodium | Diclofenac Sodium | 44 | 19 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 43 | 12 |
| Buspirone Hcl | Buspirone Hcl | 42 | 14 |
| Naproxen | Naproxen | 42 | 17 |
| Simvastatin | Simvastatin | 42 | 13 |
| Bupropion Xl | Bupropion Hcl | 40 | 13 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 40 | 14 |
| Propranolol Hcl | Propranolol Hcl | 40 | 12 |
| Baclofen | Baclofen | 38 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 38 | 21 |
| Levetiracetam | Levetiracetam | 38 | suppressed |
| Pregabalin | Pregabalin | 38 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 37 | 12 |
| Tramadol Hcl | Tramadol Hcl | 35 | 12 |
| Azelastine Hcl | Azelastine Hcl | 34 | 19 |
| Alprazolam | Alprazolam | 30 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 29 | 12 |
| Celecoxib | Celecoxib | 28 | 11 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 28 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 28 | suppressed |
| Clonazepam | Clonazepam | 27 | suppressed |
| Cephalexin | Cephalexin | 25 | 22 |
| Glipizide | Glipizide | 25 | suppressed |
| Azithromycin | Azithromycin | 24 | 23 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 24 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 24 | 11 |
| Fenofibrate | Fenofibrate Nanocrystallized | 24 | suppressed |
| Lamotrigine | Lamotrigine | 24 | suppressed |
| Methylprednisolone | Methylprednisolone | 24 | 24 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 24 | 14 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 24 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 23 | 21 |
| Farxiga | Dapagliflozin Propanediol | 23 | suppressed |
| Ibuprofen | Ibuprofen | 23 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 23 | suppressed |
| Nifedipine Er | Nifedipine | 22 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 22 | suppressed |
| Carbamazepine Er | Carbamazepine | 21 | suppressed |
| Entresto | Sacubitril/Valsartan | 21 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 21 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 21 | 17 |
| Ultra-Fine Micro Pen Needle | Pen Needle, Diabetic | 21 | suppressed |
| Eszopiclone | Eszopiclone | 20 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 20 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 20 | suppressed |
| Trulicity | Dulaglutide | 20 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 19 | suppressed |
| Ezetimibe | Ezetimibe | 19 | suppressed |
| Ondansetron Odt | Ondansetron | 19 | 14 |
| Famotidine | Famotidine | 18 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 18 | suppressed |
| Prednisone | Prednisone | 18 | 15 |
| Torsemide | Torsemide | 18 | suppressed |
| Olmesartan-Amlodipine-Hctz | Olmesartan/Amlodipin/Hcthiazid | 17 | suppressed |
| Xarelto | Rivaroxaban | 17 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 16 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 16 | suppressed |
| Estradiol | Estradiol | 16 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 16 | suppressed |
| Linzess | Linaclotide | 16 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 16 | suppressed |
| Synjardy Xr | Empagliflozin/Metformin Hcl | 16 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 16 | suppressed |
| Vraylar | Cariprazine Hcl | 16 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 16 | suppressed |
| Nitroglycerin | Nitroglycerin | 15 | suppressed |
| Aripiprazole | Aripiprazole | 14 | suppressed |
| Irbesartan | Irbesartan | 14 | suppressed |
| Topiramate | Topiramate | 14 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 14 | suppressed |
| Trijardy Xr | Empaglifloz/Linaglip/Metformin | 14 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 13 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 13 | suppressed |
| Fluconazole | Fluconazole | 13 | suppressed |
| Indomethacin | Indomethacin | 13 | suppressed |
| Lovastatin | Lovastatin | 13 | suppressed |
| Methocarbamol | Methocarbamol | 13 | suppressed |
| Tradjenta | Linagliptin | 13 | suppressed |
| Diazepam | Diazepam | 12 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 12 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 12 | suppressed |
| Dupixent Syringe | Dupilumab | 12 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 12 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 12 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 12 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 11 | suppressed |
| Atenolol | Atenolol | 11 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 11 | suppressed |
| Glimepiride | Glimepiride | 11 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 11 | suppressed |
| Januvia | Sitagliptin Phosphate | 11 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 11 | suppressed |
| Sucralfate | Sucralfate | 11 | suppressed |
| Valsartan | Valsartan | 11 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 11 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 11 | suppressed |
| Zonisamide | Zonisamide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $2,026.30 · 109 records | Novo Nordisk Inc | ABRYSVO, AIRSUPRA, AREXVY, Auvelity, Azstarys, BEXSERO, CAPLYTA, COMIRNATY, CREON, Cologuard Collection Kit, Dexcom G6 Transmitter, ELIQUIS, EVENITY, FARXIGA, FREESTYLE LIBRE 3, GEMTESA, IBSRELA, Jornay PM, Kerendia, LINZESS, MOUNJARO, NURTEC ODT, NUZYRA, OTEZLA, Ozempic, PREVNAR 20, QULIPTA, REPATHA, Rybelsus, SHINGRIX, Symbravo, TRELEGY ELLIPTA, TRULICITY, UBRELVY, VIBERZI, VOQUEZNA, VRAYLAR, Veozah, Wegovy, XIFAXAN, ZAVZPRET, ZEPBOUND | 10 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error